![Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/a10175b4-7e68-4d5f-a894-92a1f3574549/gr1.jpg)
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
![The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders | Journal of Patient-Reported Outcomes | Full Text The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders | Journal of Patient-Reported Outcomes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs41687-020-00219-4/MediaObjects/41687_2020_219_Fig1_HTML.png)
The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders | Journal of Patient-Reported Outcomes | Full Text
![The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12955-019-1220-z/MediaObjects/12955_2019_1220_Fig2_HTML.png)
The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text
![Patient-reported outcomes: A new era in clinical research Deshpande PR, Rajan S, Sudeepthi B L, Abdul Nazir C P - Perspect Clin Res Patient-reported outcomes: A new era in clinical research Deshpande PR, Rajan S, Sudeepthi B L, Abdul Nazir C P - Perspect Clin Res](https://www.picronline.org/articles/2011/2/4/images/PerspectClinRes_2011_2_4_137_86879_u4.jpg)
Patient-reported outcomes: A new era in clinical research Deshpande PR, Rajan S, Sudeepthi B L, Abdul Nazir C P - Perspect Clin Res
![The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12955-019-1220-z/MediaObjects/12955_2019_1220_Fig3_HTML.png)
The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text
![Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension | Nature Medicine Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-1034-x/MediaObjects/41591_2020_1034_Fig1_HTML.png)
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension | Nature Medicine
![Frontiers | Consensus Guidelines for Improving Quality of Assessment and Training for Neuromuscular Diseases Frontiers | Consensus Guidelines for Improving Quality of Assessment and Training for Neuromuscular Diseases](https://www.frontiersin.org/files/Articles/735936/fgene-12-735936-HTML-r1/image_m/fgene-12-735936-g001.jpg)
Frontiers | Consensus Guidelines for Improving Quality of Assessment and Training for Neuromuscular Diseases
![Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial - The Lancet Oncology Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/a3903ead-3066-41a8-9953-161d09384c00/gr1.jpg)